Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Assaf-Harofeh Medical Center |
---|---|
Information provided by: | Assaf-Harofeh Medical Center |
ClinicalTrials.gov Identifier: | NCT00697021 |
TEG is an established technique to assess the quality of clot formation' used mainly in surgery and obstetrics to determine possible bleeding diathesis. Recently it became to be used in cardiology, where it can be a valuable tool to assess a response to antiplatelet therapy and its association with the outcome. However, there is a few data about use of TEG in STEMI patients undergoing PCI. Our study is designed to assess by TEG the platelet's response to clopidogrel treatment during acute STEMI in patients undergoing primary PCI and the correlation of this response with the long term outcome, and ability to dose adjustment according to a specific measurement by TEG in order to prevent future MACE.
Condition | Intervention | Phase |
---|---|---|
Acute ST SEgment Elevation Myocardial Infarction |
Drug: Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG Drug: Aspirin 100mg and Plavix 75mg |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI |
Estimated Enrollment: | 50 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | October 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Patients who suffered acute STEMI and were treated by PPCI and by Aspirin 100mg and Plavix 75mg and showed on treatment platelet over-reactivity observed by TEG system on the 5th day after admission to ICCU
|
Drug: Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG
Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
|
2
Patients who suffered acute STEMI and were treated by PPCI and recieved by Aspirin 100mg and Plavix 75mg and showed platelet inhibition observed by TEG system on the 5th day after admission to ICCU
|
Drug: Aspirin 100mg and Plavix 75mg
Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
|
TEG system may provide the capabilities needed to deliver personalized therapy, first, because it can identify patients at risk of ischemic event based on hemostatic influences, particularly platelet aggregation and platelet reactivity. Secondly, because treating those patients who exhibit high platelet reactivity -- an indication that they are not reaching a therapeutic level -- with appropriate drugs and doses is expected to improve outcomes.
In this study that would be increased clopidogrel maintenance dosing (150 mg) or aspirin maintenance dosing to 200mg in an attempt to lower platelet reactivity below the 50th%ile, which we expect to also reduce their ischemic risk during the follow up period.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ilya Litovchik, MD | 972-5-7734-5900 | ilitovchik@gmail.com |
Contact: Alex Blatt, MD | 972-5-7734-5906 | blattalex@gmail.com |
Israel | |
Assaf Harofeh MC ICCU | Recruiting |
Zerrifin, Israel, 73000 | |
Contact: Ilya Litovchik, MD 972-5-7734-5900 ilitovchik@gmail.com | |
Contact: Alex Blatt, MD 972-5-7734-5906 blattalex@gmail.com | |
Principal Investigator: Ilya Litovchik, MD |
Principal Investigator: | Ilya Litovchik, MD | Assaf Harofeh MC Heart Institue |
Study Director: | Alex Blatt, MD | Assaf Harofeh MC ICCU Head of the Department |
Responsible Party: | Intensive Coronary Care Unit Assaf Harofeh MC ( Alex Blatt MD ) |
Study ID Numbers: | 57/08 |
Study First Received: | June 10, 2008 |
Last Updated: | June 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00697021 |
Health Authority: | Israel: Ministry of Health |
Thromboelastography Aspirin Clopidogrel Plavix Resistance Platelet |
Coronary Stenting Bare Metal Stent Dual antiplatelet therapy Overreactivity Primary Coronary Intervention |
Necrosis Heart Diseases Aspirin Clopidogrel Myocardial Ischemia |
Vascular Diseases Ischemia Infarction Myocardial Infarction |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Hematologic Agents Physiological Effects of Drugs Enzyme Inhibitors Fibrinolytic Agents Cardiovascular Agents Pharmacologic Actions Fibrin Modulating Agents Pathologic Processes |
Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Platelet Aggregation Inhibitors Cardiovascular Diseases Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |